Allergan’s supplemental new drug application (sNDA) for Vraylar (cariprazine) to treat negative symptoms associated with schizophrenia in adult patients has received a Refusal to File (RTF) letter from the US Food and Drug Administration (FDA).

Schizophrenia is a chronic and disabling disorder that leads to positive symptoms, including hallucinations, delusions and thought disorders, and negative symptoms, such as loss of motivation and social withdrawal.

The symptoms are significantly related to long-term morbidity, poor psychosocial functioning and high social and economic costs.

Vraylar an oral, once-daily atypical antipsychotic approved in the US for the treatment of patients with schizophrenia or the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder.

“We remain committed to our mental health programme and to cariprazine and its potential as a treatment option for patients suffering from negative symptoms associated with schizophrenia.”

After conducting preliminary review for the Allergan therapy, the US agency determined that the sNDA for treatment of negative symptoms was not sufficiently complete to grant a substantive review.

Allergan chief research and development officer Dr David Nicholson said: “We are disappointed with the FDA decision on our submission. We will request a meeting with FDA to discuss and determine our next steps.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Vraylar is an important treatment option for patients suffering from bipolar I disorder and schizophrenia.

“We remain committed to our mental health programme and to cariprazine and its potential as a treatment option for patients suffering from negative symptoms associated with schizophrenia.”

Discovered and co-developed by Hungarian pharmaceutical company Gedeon Richter, Vraylar is currently licensed to Allergan in the US and Canada.